scleroderma

Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern
Jean-Baptiste Vulsteke, Yves Piette, Carolien Bonroy, Patrick Verschueren, Daniel Blockmans, Steven Vanderschueren, Kristl G Claeys, Petra De Haes, Jan Leo Lenaerts, Wim A Wuyts, Takashi Matsushita, Vanessa Smith, Ellen De Langhe, Xavier Bossuyt

Annals of the Rheumatic Diseases May 2022, 81 (5) 742-744; DOI: 10.1136/annrheumdis-2021-220004
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire
Mike O Becker, Rucsandra Dobrota, Alexandru Garaiman, Rudolf Debelak, Kim Fligelstone, Ann Tyrrell Kennedy, Annelise Roennow, Yannick Allanore, Patricia E Carreira, László Czirják, Christopher P Denton, Roger Hesselstrand, Gunnel Sandqvist, Otylia Kowal-Bielecka, Cosimo Bruni, Marco Matucci-Cerinic, Carina Mihai, Ana Maria Gheorghiu, Ulf Mueller-Ladner, Joseph Sexton, Tore K Kvien, Turid Heiberg, Oliver Distler

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 507-515; DOI: 10.1136/annrheumdis-2021-220702
Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time
Brian Skaug, Marka A Lyons, William R Swindell, Gloria A Salazar, Minghua Wu, Tuan M Tran, Julio Charles, Connor P Vershel, Maureen D Mayes, Shervin Assassi

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 516-523; DOI: 10.1136/annrheumdis-2021-221352
Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
Shervin Assassi, Elizabeth R Volkmann, W Jim Zheng, Xuan Wang, Holly Wilhalme, Marka A Lyons, Michael D Roth, Donald P Tashkin

Annals of the Rheumatic Diseases Feb 2022, annrheumdis-2021-221313; DOI: 10.1136/annrheumdis-2021-221313
Epigenetic profiling of twins identify repression of KLF4 as a novel pathomechanism in systemic sclerosis
Jörg H W Distler, Steven O'Reilly

Annals of the Rheumatic Diseases Feb 2022, 81 (2) 151-152; DOI: 10.1136/annrheumdis-2021-221605
Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis
Maya Malaab, Ludivine Renaud, Naoko Takamura, Kip D Zimmerman, Willian A da Silveira, Paula S Ramos, Sandra Haddad, Marc Peters-Golden, Loka R Penke, Bethany Wolf, Gary Hardiman, Carl D Langefeld, Thomas A Medsger, Carol A Feghali-Bostwick

Annals of the Rheumatic Diseases Feb 2022, 81 (2) 268-277; DOI: 10.1136/annrheumdis-2021-221050
Anti-ANP32A antibodies in systemic sclerosis
Rachel Wallwork, Livia Casciola-Rosen, Ami A Shah

Annals of the Rheumatic Diseases Feb 2022, 81 (2) 301-302; DOI: 10.1136/annrheumdis-2021-221354
Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease
Seung Min Jung, Kyung-Su Park, Ki-Jo Kim

Annals of the Rheumatic Diseases Jan 2022, 81 (1) 108-116; DOI: 10.1136/annrheumdis-2021-220493
Effects of face masks on oxygen saturation and functional measures in patients with connective tissue disorder-associated interstitial lung disease
Anuroopa Vijayan, Sakir Ahmed, Sneha Joseph, Aswathy Sukumaran, Subin Ahmed, Padmanabha Shenoy

Annals of the Rheumatic Diseases Nov 2021, 80 (11) 1497-1498; DOI: 10.1136/annrheumdis-2021-220230
Response to: ‘Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management’’ by Snarskaya and Vasileva
Cosimo Bruni, Marco Matucci-Cerinic

Annals of the Rheumatic Diseases Jan 2021, annrheumdis-2020-219533; DOI: 10.1136/annrheumdis-2020-219533

Main menu

scleroderma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

scleroderma

Pages